Remedy Pharmaceuticals Announces Contest to Name its Subarachnoid Hemorrhage Clinical Trial

NEW YORK--()--Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced a contest to name its upcoming clinical trial in Subarachnoid Hemorrhage (SAH).

“We’re looking for an acronym that conveys the meaning of this trial”

SAH is a serious, life-threatening condition. Each year some 30,000 to 35,000 people in the U.S. are afflicted by SAH, a type of stroke caused by bleeding into the space between the brain and the skull. Remedy Pharmaceuticals is planning to begin a Phase 2a clinical study of its drug CIRARA in patients with SAH.

“We’re looking for an acronym that conveys the meaning of this trial,” notes, David Geliebter, Remedy’s Executive Chairman. “SAH is a serious subject, but it doesn’t mean we can’t have a little fun with our name contest.”

Rules and entry instructions can be found at:


CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA.


Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system (CNS) edema – including large hemispheric infarction, subarachnoid hemorrhage, and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders.


Remedy Pharmaceuticals
Sven Jacobson, 212-586-2226 x 225

Recent Stories

RSS feed for Remedy Pharmaceuticals, Inc.